Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
|
|
- Aldous Harrell
- 5 years ago
- Views:
Transcription
1 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H revenues and results - 24 July 2014
2 Forward-looking statement This presentation contains forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, notably legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. 2
3 H Highlights Growth and profitability maintained Revenues: m (+1.2%) Oralair exc. U.S: 18.1 m (+26%) EBITDA: 42.3 m (32.6% of sales) Net Cash Flow: 29.4 m (+121% vs last year) U.S: 1 st patients treated with Oralair in May, several thousand people have already yjoined support programs 2014 guidance: Confirmation of revenue and increase of EBITDA guidance In July, continued international expansion with the acquisition of ALERGO PHARMA S.R.L in Argentina 3
4 H1 2014: Stallergenes growth driven by North and Central Europe and international markets Net Sales per geographic segment (in m) 128.7m +1.0% 130.0m +22.3% +3.1% 8.2m 0.25m 30.5m International markets: Strong sales performance confirms our expansion strategy Market leader in Australia, Middle-East, and Russia, where performance is largely driven by increased prescriber and patient base -1.5% 91m North and Central Europe: Growth driven by Eastern Europe H H International markets USA North & Central Europe Southern Europe Southern Europe: France: Successful new pump launch Oralair reaches market leadership Revision of business model patterns in Italy & Spain to reflect difficult economic conditions 4
5 Major on-going projects DIVERSIFY in allergies EXPAND in asthma MAXIMISE our current business New innovative technologies (DBV Technologies, ActoGeniX) HDM tablet (STG320) in asthma (ongoing ph.ii study) Foster patients capture and retention Staloral sales acceleration through the launch of the new pump and sustained efficacy data on birch Oralair : Continuous double digit growth (+26%) HDM tablet (STG320) in Allergic Rhinitis: Positive ph.iii study results and Marketing authorization filed in Japan International expansion 5
6 Major on-going projects New innovative technologies (DBV Technologies, ActoGeniX) DIVERSIFY in allergies HDM tablet (STG320) in asthma (ongoing ph.ii study) EXPAND in asthma Foster patients capture and retention MAXIMISE our current business Staloral sales acceleration through the launch of the new pump and sustained efficacy data on birch Oralair : Continuous double digit growth (+26%) HDM tablet (STG320) in Allergic Rhinitis: Positive ph.iii study results and Marketing authorization filed in Japan International expansion 6
7 Oralair : Continuous double digit growth (+26%) Oralair : The 5 grass pollen tablet demonstrated efficacy with pre & coldiscontinued dregimen seasonal The fastest growing g AIT tablet (x20 in 6 years) Oralair gains market leadership in France in one year A major advancement in AIT treatment in the U.S A new springboard to leverage our positions in high potential countries: Turkey: Marketing Authorization granted Canada & Belgium: better reimbursement conditions 7
8 Oralair : The fastest growing AIT tablet Oralair revenues since launch (m ) Oralair market share 1 : 47% (MAT Apr. 2014) pts vs. Apr x % YTD H YTD H IMS data: only countries where both Oralair and Grazax have been launched w/o US. In MAT: Moving Annual Turnover in value 8
9 Oralair : AIT tablet sales leader in France just one year post launch Grasses tablet t Sales Grasses Tablet Market Share + 1,9 M +50% 3.7 M 5.6 M Oralair 3.0 M Oralair 39% +15% Oralair 54% Oralair 1.5 M +107% Grazax 2.3 M +13% Grazax 2.6 M Grazax 61% 15% Grazax 46% YTD May 2013 YTD May 2014 Source : GERS YTD May 2013 YTD May 2014 Source : GERS in value Oralair has been launched in France 2 years after Grazax 9
10 AIT grass tablets gaining market share Worldwide AIT Grass pollen market evolution (TO)* % +7pts 21% 3pts 50% 47% 36% 4pts 32% Sublingual Tablets Subcutaneous Sublingual drops * W/o US and Japan Stallergenes internal estimates due to incomplete available data 10
11 USA: Oralair now available for US patients Oralair approved by the FDA on April 1, 2014 Oralair is the first and only 5-grass tablet immunotherapy tablet with a pre-co seasonal protocol approved in the U.S for the treatment of grass pollen allergy Oralair launched on May 5, 2014 by Greer Laboratories Inc., a leader in allergen immunotherapy in the U.S Oralair is currently being reimbursed by the top U.S. payors representing more than 160 million covered lives Several thousand patients joined allergy patient support programs 11
12 Oralair : The 5 grass pollen tablet demonstrated efficacy with pre & co-seasonal discontinued regimen 15 1,5 Daily Combined Score Daily Combined Score (DCS) Placebo 5-Grass Pollen Tablet ± standard error 1,0 p= Treatment period Post-treatment period LS mean 0,5-16.4% p< % p< % p= % p= % 0, , , , , , n = Year 1 Year 2 Year 3 Year 4 Year 5 V053 - Didier A. Abstract EAACI 2014 Sublingual five-grass pollen tablets (Oralair): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis Katherine A. Lyseng-Williamson - Drugs Ther Perspect DOI /s Springer International Publishing Switzerland
13 House Dust Mite AIT tablet (STG320): High potential development program Ongoing major development in allergic rhinitis: House Dust Mite AIT tablet (STG320), targeting the most prevalent cause of respiratory allergies in the world Japan Positive ph.iii study results Marketing Authorization filed U.S / E.U Phase III study IND submission by Q
14 Broadening STALLERGENES' geographic footprint Accelerating growth in our new AIT markets: Latin American acquisition: ALERGO PHARMA S.R.L The leader on the AIT market in Argentina Excellent market knowledge, an extensive distribution network and long standing relations with allergy specialists Broadens STALLERGENES' geographic footprint across the region 14
15 Financials a 15
16 Strong profitability including continuous geographic expansion & USA H H Change M % % % Net sales Total Revenues Gross Margin (2.5) SG & A (53.6) (41.7) (52.0) (40.0) (3.0) R&D cost (22.2) (17.2) (22.5) (17.3) +1.5 R&D revenue Current Op Result Transformation (2.8) (2.2) (3.3) (2.6) 17.9 EBIT Net Result Current Operating result grows faster than Net Sales thanks to well managed Operating Expenses and higher R&D revenue and despite a deterioration in Gross Margin 16
17 Net Cash Flow up 121% H H Change M % EBIT EBITDA Operating income tax (11.3) (10.7) Working Capital variance (11.2) 4.6 Capital expenditures (5.0) (5.2) Free Cash Flow Financing Activities (0.8) (1.6) Net Cash Flow Improved Net Cash Flow primarily thanks to a milestone payment from our Japanese partner 17
18 Debt to equity ratio up to 74% vs. 66% in prior year June 30, 2013 June 30, Change 2014 M % Non current assets (0.3) Current assets Cash TOTAL ASSETS Shareholders equity Long term liabilities (6.5) Short term liabilities TOTAL LIABILITY AND SHAREHOLDERS EQUITY
19 Revised 2014 Guidance Revenues: Low single digit growth EBITDA: 28% of net sales 1 1 excluding non current income and expenses 19
20 Main takeaways Oralair expansion in the United States, a major market for future growth Strong product portfolio for the 3 main allergens (grass & birch pollen, house dust mites) Further international development, particularly in Latin America 2014 guidance: Confirmation of revenue and increase of EBITDA guidance 20
A world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More informationA world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP
A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationLeading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products
ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio
More informationMoving closer to people with allergy
Moving closer to people with allergy Investor Relations Presentation January 2017 1 I Investor Relations Presentation January 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations Presentation April 2017 1 I Investor Relations presentation April 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationWe improve quality of life by preventing and curing allergy
We improve quality of life by preventing and curing allergy SEB Enskilda Nordic Small & Mid Cap Seminar 2008 Jens Bager, President & CEO ALK-Abelló a fast growing pharmaceutical company Global pharmaceutical
More informationALK-Abelló A/S. Click View,Header and Footer to change this text to filename and department name
ALK-Abelló A/S June 25, 2008 Click View,Header and Footer to change this text to filename and department name 1 Changing the way we treat allergy Piper Jaffray 19th Annual Health Care Conference, New York
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy General Investor Presentation February 2016 1 I ALK at a glance Commercial leader and foremost innovator within respiratory diseases World leader in allergy immunotherapy
More informationThe leading allergy specialist with a history dating back to 1923
The leading allergy specialist with a history dating back to 1923 7% 4 year CAGR 11% 4 year CAGR 33% of global allergy immunotherapy market 2012 Revenue: DKK 2.35b (EUR 314m) 2012 EBITDA: DKK 306m (EUR
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationALK at a glance The leading allergy specialist
ALK at a glance The leading allergy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise tablet portfolio Modern allergy
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationAllergy Therapeutics. Corporate Presentation. Proactive Investors 28th January 2016 Ian Postlethwaite, Finance Director
Allergy Therapeutics Corporate Presentation January 2016 Introduction We treat people with Allergic disorders Focused on the moderate to severe patients Providing treatments that cure the disease, not
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationPhotoCure ASA. Presentation. Results 1 Quarter 2004
PhotoCure ASA Presentation Results 1 Quarter 2004 7 th of May 2004 Progress towards sustained profitability Continued product roll out Metvix European sales continue to grow Final US approval for Actinic
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationGROWTH NOW! Franck Riboud
GROWTH NOW! Franck Riboud June 15 h, 2010 Disclaimer This document contains certain forward-looking statements concerning DANONE. Although DANONE believes its expectations are based on reasonable assumptions,
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy R&D and Business Briefing New York, May 2014 ALK s equity story An emerging speciality pharma with a global growth strategy Jens Bager President and CEO Today s
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationLetter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationNomura Healthcare Conference
Nomura Healthcare Conference Sebastien Martel Head of Investor Relations London, July 1st, 2011 Forward Looking Statements 2 This presentation contains forward-looking statements as defined in the Private
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationALK-Abelló Research & Development. Henrik Jacobi MD, EVP Research & Development
ALK-Abelló Research & Development Henrik Jacobi MD, EVP Research & Development Agenda Latest news on GRAZAX 3rd year data from long-term study (GT-08) Effect on asthma symptoms in children (GT-12) Status:
More informationImmunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007
Immunity for Life TM Third Quarter 2007 CEO Lars Viksmoen CFO Finn Samuelsen 31 October 2007 Operational Highlights for Q3 2007 Clinical phase III study with SBG for treatment of diabetic ulcers; enrolment
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationColoplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
More informationTherapeutic products for respiratory and autoimmune diseases. Annual General Meeting
Therapeutic products for respiratory and autoimmune diseases Annual General Meeting November 2007 Summary Objective Lead products Discovery Listings Location Facility Employees Cash (30/6/07) Shares outstanding
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationSecond Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1
Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including
More informationo Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH Publishing Date: July, 2017
o Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH-10401 Publishing Date: July, 2017 Sr. No. License Type Price 1 Single User License $4,175.00 2 Multiple User
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationSlide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More information27 September Interim results for the six months ended 30 June 2018
27 September 2018 Interim results for the six months ended 30 June 2018 Disclaimer 2 Neither this presentation nor any verbal communication shall constitute, or form part of, any offer, invitation or inducement
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationElekta Innovation and Growth. ESTRO 2012 Capital Markets Presentation
Elekta Innovation and Growth ESTRO 2012 Capital Markets Presentation 15.00 Introduction Partner in cancer care Growth Tomas Puusepp President and CEO 15.30 Patient-focused development Cancer care solutions
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationThe New Danone : A unique food company. Autumn Conference 2008 CA Cheuvreux
The New Danone : A unique food company Autumn Conference 2008 CA Cheuvreux September 26th, 2008 Disclaimer This document contains certain forward-looking statements concerning Groupe DANONE. Although Groupe
More informationTHE NEXT GROWTH PHASE
THE NEXT GROWTH PHASE Investor Briefing Non-Deal Roadshow March 2019 Melbourne Sydney CLINUVEL PHARMACEUTICALS LTD Darren Keamy, Chief Financial Officer Malcolm Bull, Investor Relations Manager ASX: CUV
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationCYCLOTRONS WORLD MARKET REPORT & DIRECTORY EDITION TOC and Summary USED IN NUCLEAR MEDICINE MARKET DATA, COMPANIES PROFILES.
CYCLOTRONS USED IN NUCLEAR MEDICINE WORLD MARKET REPORT & DIRECTORY MARKET DATA, COMPANIES PROFILES TOC and Summary EDITION 2015 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/5
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationMore information at
Report Information More information at https://www.htfmarketreport.com/reports/1288313 Global Homeopathic Products Market Professional Survey Report 2018 Report Code: HTF1288313 Pages: 111 Price: 1-User
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationFirst Quarter Results to March 31, Shire plc April 25, 2008
First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationStrategic Business Overview. Bernard HOURS
Strategic Business Overview Bernard HOURS 2000-2007: Continuous growth 8% Volume 10% Sales 14% EBIT 7% 6% 5% 4% 3% 2% 1% 9% 8% 7% 6% 5% 4% 3% 2% 1% 12% 10% 8% 6% 4% 2% 0% 0% 0% 2000 2007 2000 2007 2000
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationCochlear Limited Results for the half year ended 31 December 2007
Cochlear Limited Results for the half year ended 31 December 2007 Chris Roberts Chief Executive Officer Neville Mitchell Chief Financial Officer Cochlear Overview Medical device company (~26yr): global
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationForward Looking Statements
Therapeutic products for respiratory diseases September 2008 Forward Looking Statements This presentation may contain forward-looking statements that are based on management s current expectations and
More informationAnnual Figures 2017/18. Burgdorf, 24 May 2018
Annual Figures 2017/18 Burgdorf, 24 May 2018 Important information The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More information